Table 2. Linear regression analysis of prognostic factors.
| Beta value | Power | |
|---|---|---|
| Intercept | +0.09±0.20 | 0.65 |
| Age (in years) | +0.001±0.002 | 0.64 |
| Switch to bevacizumab/ranibizumab | +0.03±0.05 | 0.53 |
| Visual acuity before switch (log10) | +0.19±0.08 | 0.02 |
| Change of visual acuity before switch | −0.10±0.10 | 0.30 |
| Macular thickness before switch (in μm) | <−0.001±<0.001 | 0.14 |
| Stratus/Spectralis OCT | −0.04±0.05 | 0.38 |